Piecing Together the Pricing Puzzle: The Midterm Elections

There is no magic bullet that will dramatically impact drug pricing to everybody s liking patients, industry, and government. But a stepwise approach involving a series of changes, including taking advantage of the next midterm elections, could point the path toward a solution Powered by WPeMatico Continue reading Piecing Together the Pricing Puzzle: The Midterm Elections

Reflections from #Asembia18: The State of Specialty Pharmacy 2018

Last week, Paula and I had the pleasure of attending Asembia’s 2018 Specialty Pharmacy Summit. The Specialty Pharmacy Summit remains the most important forum in the specialty marketplace. This year, a record 6,500 people learned, networked, and connected in Las Vegas. It was another year of record attendance. (Here’s the official press release.) Drug Channels again salutes Larry and Robert Irene for sustaining and growing an annual event that unites the entire industry. Today marks the eighth year that I will violate Vegas code and tell you what happened there. Below, I offer reflections on the meeting and highlight key … Continue reading Reflections from #Asembia18: The State of Specialty Pharmacy 2018

The Top 15 Specialty Pharmacies of 2017: PBMs and Payers Still Dominate (rerun)

This week, I’m rerunning some popular posts while I attend Asembia’s 2018 Specialty Pharmacy Summit. Click here to see the original post and comments from March 2018. Below is our exclusive Drug Channels Institute list of the 15 largest pharmacies, ranked by estimated 2017 revenues from dispensing specialty pharmaceuticals. The battle for control of the specialty market accelerated in 2017, though pharmacies owned by pharmacy benefit managers (PBMs) continued to capture most of the market share. The top four specialty pharmacies are all owned or co-owned by a PBM. They accounted for about two-thirds of prescription revenues from pharmacy-dispensed specialty … Continue reading The Top 15 Specialty Pharmacies of 2017: PBMs and Payers Still Dominate (rerun)

The Gross-to-Net Bubble Topped $150 Billion in 2017

In 2017, the gross-to-net bubble—the ever-growing pile of money between a manufacturer’s list price for a drug and the net price after rebates and other reductions—hit a new high. Based on new data from IQVIA, manufacturers of brand-name drugs in 2017 reduced list price revenues by an astonishing $153 billion. Those reductions came primarily from rebates, discounts, and other payments to the drug channel. That figure has grown by 10% from the 2016 figure, even though net prices for brand-name drugs grew by only 1.9%. We can no longer ignore the warped incentives created by our bubble buddy. As regular … Continue reading The Gross-to-Net Bubble Topped $150 Billion in 2017

EXCLUSIVE: A Record Number of Specialty Pharmacies Now Have Accreditation

It’s time for Drug Channels Institute’s annual update on the accreditation of specialty pharmacies. Our spooky research team (pictured at right) is back! We have counted every pharmacy location that has achieved accreditation by an independent organization. Our exclusive findings: The number of specialty pharmacies with accreditation expanded again in 2017. We identified 729 unique pharmacy locations that by the end of 2017 had achieved accreditation from the three major independent accreditation organizations. The 2017 figure is almost double the 2015 figure. For the second consecutive year, pharmacy locations owned by healthcare providers—such as hospitals, health systems, physician practices, and … Continue reading EXCLUSIVE: A Record Number of Specialty Pharmacies Now Have Accreditation

The Top 15 Specialty Pharmacies of 2017: PBMs and Payers Still Dominate

Below is our exclusive Drug Channels Institute list of the 15 largest pharmacies, ranked by estimated 2017 revenues from dispensing specialty pharmaceuticals. The battle for control of the specialty market accelerated in 2017, though pharmacies owned by pharmacy benefit managers (PBMs) continued to capture most of the market share. The top four specialty pharmacies are all owned or co-owned by a PBM. They accounted for about two-thirds of prescription revenues from pharmacy-dispensed specialty drugs. Vertical integration M&A has been in the news. But as our data shows, the integration of PBMs and specialty pharmacies has already happened. Read more » … Continue reading The Top 15 Specialty Pharmacies of 2017: PBMs and Payers Still Dominate

NEW: The 2018 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

I am pleased to announce our new our 2018 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers, available for purchase and immediate download. Click here to download a free report overview (including the Table of Contents and a List of Exhibits) Click here to read the press release We’re offering special discounted pricing if you order before March 10, 2018! The 2018 edition has been thoroughly updated, revised, and expanded. This latest edition contains the most current financial and industry data along with information about the strategies and market positions of the largest companies. Many sections and chapters have … Continue reading NEW: The 2018 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

The Top 15 U.S. Pharmacies of 2017: Market Shares and Key Developments For The Biggest Companies

Next week, Drug Channels Institute will release our 2018 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. It’s the ninth edition of our popular examination of the U.S. pharmacy distribution and reimbursement system. The exhibit below—one of 160 in our new report—provides a first look at the 15 largest pharmacies, ranked by total U.S. prescription dispensing revenues for calendar year 2017. I also highlight crucial market changes that affected our ranking. As you will see, the big got bigger in 2017. For a sneak peek at the complete report, download the free overview. If you would like to preorder … Continue reading The Top 15 U.S. Pharmacies of 2017: Market Shares and Key Developments For The Biggest Companies

New Express Scripts Data: The Drug Spending Slowdown Is Real

Last week, Express Scripts released its 2017 Drug Trend Report. (Free download.)  Consider it an early Valentine’s Day present for pharma wonks like your friendly neighborhood blogger. The latest data confirm the slowdown in drug spending. For 2017, drug spending increased by only 1.5% for Express Scripts’ commercial plan sponsors. What’s more, drug spending declined for nearly half of commercial payers. Medicare, Medicaid, and exchange plans also saw very modest increases. Below, I dive deep into the data on cost and utilization growth. By now, there can be no debate that pharmacy benefit costs are growing more slowly than every … Continue reading New Express Scripts Data: The Drug Spending Slowdown Is Real